Fragile X syndrome.

Area of Science:

• Genetics
• Neuroscience
• Developmental Biology

Background:

• Fragile X Syndrome (FXS) is a genetic disorder resulting from CGG trinucleotide expansion in the FMR1 gene.
• This expansion leads to promoter hypermethylation, silencing the gene and reducing FMR1 protein, crucial for synaptic plasticity.
• FXS manifests as intellectual disability, autism, hyperactivity, and distinct physical features, with girls often less severely affected.

Purpose of the Study:

• To review the genetic basis, clinical manifestations, diagnostic advancements, and therapeutic strategies for Fragile X Syndrome.
• To highlight the evolution of diagnostic methods from karyotyping to sensitive molecular techniques.
• To discuss the potential of pharmaceutical interventions for FXS.

Main Methods:

• Review of genetic mechanisms of CGG trinucleotide expansion.
• Analysis of clinical phenotypes associated with full mutation and premutation.
• Evaluation of diagnostic techniques including PCR and Southern Blot.
• Assessment of emerging pharmaceutical treatments.

Main Results:

• The FMR1 gene's CGG repeat expansion is the primary cause of FXS.
• Molecular diagnostic methods offer improved sensitivity and specificity over traditional karyotyping.
• Preliminary studies indicate potential efficacy of minocycline and sertraline in managing FXS symptoms in children.

Conclusions:

• Accurate diagnosis of FXS relies on advanced molecular genetic testing.
• Targeted pharmaceutical treatments are showing promise for managing FXS symptoms.
• Continued research into FMR1 gene function and therapeutic interventions is vital for improving patient outcomes.